Latest Articles

Publication Date
Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival bioengineer.org

Published: Oct. 14, 2025, 5:14 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer CancerNetwork

Published: Oct. 13, 2025, 10:05 p.m.
Researchers awarded $11.2M grant to close endometrial cancer survival gap - UNC Gillings School of Global Public Health

Researchers awarded $11.2M grant to close endometrial cancer survival gap UNC Gillings School of Global Public Health

Published: Oct. 9, 2025, 4:10 p.m.
TGFB1/SMAD3-Driven Macrophage-Myofibroblast Transition Promotes Fibrosis Progression in Endometriosis.

Endometriosis is a chronic gynecological disorder characterized by progressive fibrosis, which is closely associated with clinical symptoms such as dysmenorrhea and infertility. While myofibroblast activation is central to fibrogenesis, the …

Published: Oct. 7, 2025, midnight
Molecular Pathogenesis of Ovarian Endometrioma: Mechanistic Insights and Therapeutic Implications.

Ovarian endometrioma (OMA), the most prevalent and clinically consequential subtype of endometriosis, represents a chronic inflammatory disorder characterized by ectopic endometrial-like lesions. This condition manifests as progressive dysmenorrhea, ovarian reserve …

Published: Oct. 4, 2025, midnight
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 - BioSpace

Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 BioSpace

Published: Oct. 3, 2025, 10:53 a.m.
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 - Morningstar

Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775 Morningstar

Published: Oct. 2, 2025, 12:08 p.m.
Clinicopathological Characteristics and Oncologic Outcomes of Endometrioid Ovarian Carcinoma: A Retrospective Study from a Tertiary Cancer Centre.

Background/Objectives: To evaluate the clinicopathological features, treatment, and survival outcomes and to identify independent prognosticators for recurrence and mortality in patients with endometrioid ovarian cancer. Methods: The medical records of …

Published: Sept. 28, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!